Acrivon Therapeutics, Inc. Common Stock

ACRVNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
1.43 USD
↘ 0.12 (7.74%)AT CLOSE (11:59 AM EDT)
1.42
↘ 0.01 (0.70%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
1.42
↘ 0.01 (0.70%)
🔴Market: CLOSED
Open?$1.54
High?$1.54
Low?$1.41
Prev. Close?$1.55
Volume?546.3K
Avg. Volume?501.1K
VWAP?$1.45
Rel. Volume?1.09x
Bid / Ask
Bid?$1.35 × 1.9K
Ask?$1.44 × 2.1K
Spread?$0.09
Midpoint?$1.40
Valuation & Ratios
Market Cap?61.2M
Shares Out?42.8M
Float?14.4M
Float %?45.6%
P/E Ratio?N/A
P/B Ratio?0.64
EPS?-$1.81
Dividend?0.00%
Ex-Dividend?N/A

Acrivon Therapeutics, Inc. Common Stock (ACRV) trades at $1.43 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, ACRV appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyHealthcare - Genomics & Precision Medicine›Precision Medicine Platforms
Employees
76
Market Cap
61.2M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.acrivon.com
Listed
2022-11-15
Address
480 ARSENAL WAY, SUITE 100
WATERTOWN, MA 02472
Phone: 617-207-8979
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
31
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.37Distress
Confidence?51%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.34%High
Short Interest?2.5M
Days to Cover?4.4
Free Float14.4M
Avg Daily Volume563.2K
Settlement Date2026-05-15
Financial Health
Current Ratio?8.98Strong
Quick Ratio?8.98Strong
Cash Ratio?3.08Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.64CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-80.9%WEAK▾
ROA?
S&P
3
-71.7%WEAK▾
Cash Flow & Enterprise
FCF?$-66293000
Enterprise Value?$27.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist